Cymbalta news

Discussion in 'Fibromyalgia Main Forum' started by enlightened1, Oct 26, 2008.

  1. enlightened1

    enlightened1 New Member

    October 24, 2008
    EMEA recommends against Eli Lilly's, Boehringer Ingelheim's Cymbalta for fibromyalgia
    by Anna Bratulic

    The European Medicines Agency's Committee for Medicinal Products for Human Use recommended against extended approval for Eli Lilly's and Boehringer Ingelheim's Cymbalta (duloxetine) as a treatment for fibromyalgia.

    The committee concluded that the effectiveness of the drug in treating the disease had not been sufficiently shown and that the treatment's benefits did not outweigh its risks. James Russell, global medical director for Cymbalta at Eli Lilly, stated that the drugmakers "remain confident in the duloxetine data." To support their application, the companies submitted data from four placebo-controlled studies involving 1411 patients and one open-label safety study with 350 patients. Currently, there are no medications approved in the EU to treat the disease.

    Cymbalta has been approved in the EU for the treatment of diabetic peripheral neuropathic pain, major depressive episodes, generalised anxiety disorder and stress urinary incontinence. In June, US regulators granted marketing authorisation for the drug for the management of fibromyalgia.